Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of liver samples from Macaca fascicularis treated with varying doses of ciprofibrate for 4 or 15 days


ABSTRACT: Liver gene expression was examined in male cynomolgus monkeys treated with ciprofibrate (PPAR-alpha agonist) for 4 days at 400 mg/kg/day and treated for 15 days at 0, 3, 30, 150 or 400 mg/kg/day. The untreated control group were given only the vehicle (0.5% hydroxypropyl methylcellulose). Two animals per group were used for the 4 day treatment and four animals per group were used for the 15 day treatment (except the 15 day control group, which had three animals). Selection of significantly changed probesets was done using Rosetta Resolver and the fold-change and p values as determined by Resolver are given below. Affymetrix CEL files and MAS5-processed data have been made availabe for convenience. Note that data processing reported in the Toxicological Sciences manuscript was done using Rosetta Resolver and the treated versus control group fold-change and p-value are appended to the Series entry. An article has been published in Toxicological Sciences regarding this dataset; the data interpretation was based on the Rosetta Resolver data. Experiment Overall Design: Groups consisted of (i) vehicle only for 4 days, (ii) 400 mg/kg/day ciprofibrate for 4 days, (iii) vehicle only for 15 days and (iv) 3, 30, 150, or 400 mg/kg/day ciprofibrate for 15 days.

ORGANISM(S): Macaca fascicularis

SUBMITTER: Neal Cariello 

PROVIDER: E-GEOD-2853 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver.

Cariello Neal F NF   Romach Elizabeth H EH   Colton Heidi M HM   Ni Hong H   Yoon Lawrence L   Falls J Greg JG   Casey Warren W   Creech Donald D   Anderson Steven P SP   Benavides Gina R GR   Hoivik Debie J DJ   Brown Roger R   Miller Richard T RT  

Toxicological sciences : an official journal of the Society of Toxicology 20050804 1


Fibrates, such as ciprofibrate, fenofibrate, and clofibrate, are peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists that have been in clinical use for many decades for treatment of dyslipidemia. When mice and rats are given PPARalpha agonists, these drugs cause hepatic peroxisome proliferation, hypertrophy, hyperplasia, and eventually hepatocarcinogenesis. Importantly, primates are relatively refractory to these effects; however, the mechanisms for the species differences are  ...[more]

Similar Datasets

2005-08-23 | GSE2853 | GEO
2006-12-31 | E-MEXP-33 | biostudies-arrayexpress
2020-10-27 | GSE110528 | GEO
2007-05-16 | GSE4766 | GEO
2006-02-08 | GSE2742 | GEO
2016-07-29 | GSE84925 | GEO
2017-09-11 | PXD005958 | Pride
2017-09-11 | PXD006894 | Pride
2017-09-11 | PXD005959 | Pride
2010-06-10 | E-GEOD-22263 | biostudies-arrayexpress